286 related articles for article (PubMed ID: 31300231)
1. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD.
Rinella ME; Tacke F; Sanyal AJ; Anstee QM;
J Hepatol; 2019 Oct; 71(4):823-833. PubMed ID: 31300231
[TBL] [Abstract][Full Text] [Related]
2. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.
Rinella ME; Tacke F; Sanyal AJ; Anstee QM;
Hepatology; 2019 Oct; 70(4):1424-1436. PubMed ID: 31287572
[TBL] [Abstract][Full Text] [Related]
3. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
[TBL] [Abstract][Full Text] [Related]
4. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
[TBL] [Abstract][Full Text] [Related]
5. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.
Sanyal AJ; Friedman SL; McCullough AJ; Dimick-Santos L; ;
Hepatology; 2015 Apr; 61(4):1392-405. PubMed ID: 25557690
[TBL] [Abstract][Full Text] [Related]
6. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
7. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
[TBL] [Abstract][Full Text] [Related]
8. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
10. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
11. Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis.
Patikorn C; Veettil SK; Phisalprapa P; Pham T; Kowdley KV; Chaiyakunapruk N
Ann Hepatol; 2021; 24():100315. PubMed ID: 33515800
[TBL] [Abstract][Full Text] [Related]
12. A critical review of endpoints for non-cirrhotic NASH therapeutic trials.
Ratziu V
J Hepatol; 2018 Feb; 68(2):353-361. PubMed ID: 29223369
[TBL] [Abstract][Full Text] [Related]
13. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
Vilar-Gomez E; Chalasani N
J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
[TBL] [Abstract][Full Text] [Related]
16. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
17. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
[TBL] [Abstract][Full Text] [Related]
18. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
19. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
20. Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows.
Rowe IA
Semin Liver Dis; 2020 Nov; 40(4):339-345. PubMed ID: 32906165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]